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Background
Abstract Objective. The use of bisphosphonates (zole-
dronic acid) in the treatment of metastatic bone disease
and osteoporosis has been raised during recent years.
The purpose of this treatment is mainly to reduce skele-
tal-related events, e.g. pain and pathological fractures.
Bisphosphonate-related osteonecrosis of the jaw.
(BRONJ) adversely affects the quality of life, producing
significant morbidity in afflicted patients. BRONJ can
develop spontaneously or after minor trauma. In
general, these patients seem to have less severe manifes-
tations of necrosis and respond more readily to stage-
specific treatment regimens (Table 1). Strategies for the
treatment of patients with, or at risk of, BRONJ we reset
forth in the American Association of Oral and Maxillo-
facial Surgeons (AAOMS) Position Paper on Bispho-
sphonate-Related Osteonecrosis of the Jaws (Position
Paper) and approved by the Board of Trusteesin
September 2006.
1This update contains revisions to the
diagnosis and staging and management strategie sand
highlights the status of basic science research. We to
report the incidence of bisphosphonate-related osteone-
crosis of the jaw (ONJ), since the initiation of a routine
maxillofacial examination before treatment with bispho-
sphonates, no ONJ has been seen.
Conclusions
ONJ is a rare but a very serious complication in relation
to treatment with bisphosphonates. To decrease the
incidence of ONJ, a maxillofacial examination could be
performed in all patients before treatment with
bisphosphonates.
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BRONJ*
Stage
Description Treatment Strategies†‡§
At risk
category
No apparent necrotic bone in patients who have been treated with either oral or IV
bisphosphonates
No treatment indicated Patient
education
Stage 0 No clinical evidence of necrotic bone, but nonspecific clinical findings and symptoms Systemic management, including use
of pain medication and antibiotics
Stage 1 Exposed and necrotic bone in asymptomatic patients without evidence of infection Antibacterial mouth rinse
Clinical follow-up on quarterly basis
Patient education and review of
indications for continued
bisphosphonate therapy
Stage 2 Exposed and necrotic bone associated with infection as evidenced by pain and erythema in
region of exposed bone with or without purulent drainage
Symptomatic treatment with oral
antibiotics
Oral antibacterial mouth rinse
Pain control
Superficial debridement to relieve soft
tissue irritation
Stage 3 Exposed and necrotic bone in patients with pain, infection, and one or more of the following:
exposed and necrotic bone extending beyond the region of alveolar bone, (ie, inferior border
and ramus in the mandible, maxillary sinus and zygoma in the maxilla) resulting in pathologic
fracture, extraoral fistula, oral antral/oral nasal communication, or osteolysis extending to the
inferior border of the mandible or the sinus floor
Antibacterial mouth rinse
Antibiotic therapy and pain control
Surgical debridement/resection for
longer term palliation of infection and
pain
Abbreviations: BRONJ, bisphosphonate-related osteonecrosis of the jaw; IV, intravenous.
*Exposed bone in maxillofacial region without resolution within 8-12 weeks in persons treated with bisphosphonate who have not undergone radiotherapy to
jaws.
†Regardless of disease stage, mobile segments of bony sequestrum should be removed without exposing uninvolved bone;extraction of symptomatic teeth
within exposed, necrotic bone should be considered because it is unlikely that extraction will exacerbate established necrotic process.
‡Discontinuation of IV bisphosphonates has shown no short-term benefit. However, if systemic conditions permit,long-term discontinuation might be beneficial
in stabilizing established sites of BRONJ, reducing risk of new site development,and reducing clinical symptoms. Risks and benefits of continuing bisphosphonate
therapy should be made only by treating oncologist in consultation with oral and maxillofacial surgeon and patient.
§Discontinuation of oral bisphosphonate therapy in patients with BRONJ has been associated with gradual improvement in clinical disease. Discontinuation of
oral bisphosphonates for 6-12 months may result in either spontaneous sequestration or resolution after debridement surgery. If systemic conditions permit,
modification or cessation of oral bisphosphonate therapy should be done in consultation with treating physician and patient.
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